The in vitro activities of the macrolide antibiotics clarithromycin, 14-hydroxy-clarithromycin, azithromycin, and erythromycin against 19 isolates ofBorrelia burgdorferi were investigated. MICs ranged from 0.003 to 0.03 ,ug of clarithromycin per ml, 0.007 to 0.03 ,g of 14-hydroxyclarithromycin per ml, 0.003 to 0.03 ,ug of azithromycin per ml, and 0.007 to 0.06 ,ug of erythromycin per ml. Time-kill studies using the B31 strain of B. burgdorferi demonstrated a >3-log1o-unit killing after 72 h with each of the macrolide antibiotics tested in concentrations representing twice the respective MICs.
The variability of the clinical course of Lyme disease, a multisystemic illness caused by the spirochete Borrelia burgdorferi, has made evaluation of the effectiveness of antimicrobial therapy difficult. Although B. burgdorferi has been reported to be susceptible to a number of antibiotics, including penicillin, amoxicillin, tetracycline, doxycycline, and erythromycin (2, 4) , clinical experience has not always correlated with in vitro results (6) . For example, erythromycin is extremely active against B. burgdorferi in vitro, but it has been clinically less effective than tetracycline, doxycycline, or penicillin in the treatment of early Lyme disease (16) . Preac-Mursic and colleagues have previously reported excellent in vitro activity with the newer macrolide antibiotics clarithromycin, azithromycin, and roxithromycin against limited numbers of B. burgdorferi isolates (11) . The newer macrolide antibiotics are more rapidly absorbed, have a longer elimination half-life, and appear to be better tolerated than erythromycin (3, 10) . In addition, they penetrate tissue well and maintain high levels there (3, 5, 15) . These features suggest that clarithromycin and azithromycin may be more useful than erythromycin in the treatment of Lyme disease.
In this study we used broth microdilution MICs, MBCs determined by subsurface plating, and time-kill studies to determine the susceptibility of B. burgdorferi to macrolide antibiotics in vitro. The drugs tested were erythromycin and azithromycin (Pfizer, Groton, Conn.) and clarithromycin and the major human metabolite of clarithromycin, 14-hydroxyclarithromycin (Abbott Laboratories, North Chicago, Ill.). Antibiotics were reconstituted in the diluents recommended by their manufacturers. Nineteen human, tick, and mouse isolates of B. burgdorferi from North America, Europe, and Russia were studied. Included in this group were lowpassage (<10 passages in vitro) and high-passage isolates of the same strains and two mutant isolates that lacked the major outer membrane proteins of B. burgdorferi (Table 1) .
One isolate of Borrelia hermsii, an agent of tick-borne relapsing fever, was also studied.
MICs were determined by a broth microdilution method previously described (2) . Briefly, antibiotics were diluted twofold in BSK II medium (1) tion to be tested was dispensed into microtiter tray wells in triplicate rows. In addition, 100 ,l of BSK II medium was dispensed into wells of each microtiter tray for growth controls of each strain tested and for negative controls. The ranges of antibiotic concentrations tested were 0.0018 to 0.5 ug/ml. Clarithromycin and 14-hydroxyclarithromycin were tested in combination at a fixed 4:1 ratio in an effort to stimulate the ratio observed in human serum following administration of clarithromycin. All wells except negative control wells were inoculated with 10 ,u of actively growing cultures of borrelias propagated in BSK II medium and adjusted to yield a final inoculum of ca. 106 cells per ml as determined by enumeration with a Petroff-Hausser chamber and phase-contrast microscopy. Microdilution trays were sealed with sterile plastic adhesive and incubated for 72 h at 34°C. The lowest concentration of antibiotic that showed inhibition of visual turbidity and lack of color change from pink to yellow of the BSK II medium indicator as compared with the growth control was interpreted as the MIC. Color discrimination, particularly with low-passage strains, was improved after MIC plates had been held at 4°C for 2 to 3 h (14) .
MBCs of clarithromycin, 14-hydroxyclarithromycin, azithromycin, and erythromycin were determined in duplicate by a subsurface plating method previously described (2) . The medium for subsurface plating consisted of a 2x concentrate of BSK II medium without gelatin, a 3% bottom agarose, and a 2% top agarose. Briefly, spirochete suspensions were prepared in 2x BSK II medium and 100 ,ul was added to aliquots of molten agarose and 2x BSK II. After being vortexed gently, suspensions were poured immediately onto the surface of 2 x BSK II agar. Plates were rotated gently to spread the suspension evenly, the agarose was allowed to solidify, and plates were incubated in a candle jar at 34°C. Plates were examined visually and colonies were counted after 10 to 12 days of incubation.
At the time that microdilution trays were inoculated, the actual inoculum density of each MIC or MBC test was determined by subsurface plating as described previously (2) . After 72 h of incubation and determination of MICs, 10 ,u from each microdilution well determined to contain the MIC and above was mixed with 100 pI of 2 x BSK II medium and subcultured by subsurface plating. After 10 to 12 days, plates were examined and colonies were counted. The lowest concentration of antibiotic showing 299 the final inoculum was designated the MBC (9 The B31 strain of B. burgdorferi was used generation times in BSK II medium and rates clarithromycin, 14-hydroxyclarithromycin, and erythromycin in concentrations represent the respective microdilution MIC. Polystyret taining 10 ml of BSK II medium with the antit trations to be tested and one tube without an inoculated with 100 ,ul of an actively growin justed to yield a final inoculum of ca. 10°cells I were incubated at 34°C. At 0, 24, 48, and 72 gently vortexed and spirochete numbers for e; estimated with a Petroff-Hausser counting c estimated numbers were used to determine needed to provide countable plates followir plating. Plates were examined and colonies i after 10 to 12 days of incubation. A bactericih defined by a >3-log1o-unit killing (99.9%) of ti lum (9) .
MICs ranged from 0.003 to 0.03 ,ug of clarit ml, 0.007 to 0.03 ,ug of 14-hydroxyclarithron 0.003 to 0.03 ,ug of azithromycin per ml, and 0.1 of erythromycin per ml for the isolates of E tested. The MICs for 50 and 90% of isolates t MIC range of each antibiotic are shown in Tabl mycin and 14-hydroxyclarithromycin tested ir in a fixed 4:1 ratio showed no greater activity al Time-kill studies with clarithromycin, 14-hydroxyclawere counted rithromycin, azithromycin, and erythromycin in concentradal effect was tions representing two times the respective MIC demonie final inocustrated a >3-log1o-unit killing (99.9%) of the final inoculum (Fig. 1) (7, 12) . Conflicting data have been reported on the efficacy of azithromycin in the treatment of Lyme disease. Massarotti and colleagues reported comparable efficacy with azithromycin, amoxicillin plus probenecid, and doxycycline when given for 10 days for the treatment of early Lyme disease (8) . However, Luft et al. reported that azithromycin given daily for 1 week was significantly less effective than amoxicillin given for 3 weeks in the treatment of erythema migrans (7) .
Clinical trials of clarithromycin in the treatment of Lyme disease are in progress. While the newer macrolide antibiotics show promise for the treatment of Lyme disease, definition of their role awaits more extensive clinical studies.
